The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, Axsome Therapeutics Inc’s stock clocked out at $137.4, down -2.46% from its previous closing price of $140.86. In other words, the price has decreased by -$2.46 from its previous closing price. On the day, 0.49 million shares were traded. AXSM stock price reached its highest trading level at $140.895 during the session, while it also had its lowest trading level at $136.415.
Ratios:
To gain a deeper understanding of AXSM’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.50 and its Current Ratio is at 1.57. In the meantime, Its Debt-to-Equity ratio is 2.96 whereas as Long-Term Debt/Eq ratio is at 1.97.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, B. Riley Securities on October 01, 2025, initiated with a Buy rating and assigned the stock a target price of $179.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 05 ’25 when Herriot Tabuteau bought 21,775 shares for $135.69 per share.
TABUTEAU HERRIOT sold 91,705 shares of AXSM for $12,136,240 on Nov 03 ’25. The Chief Executive Officer now owns 7,229 shares after completing the transaction at $132.34 per share. On Nov 04 ’25, another insider, TABUTEAU HERRIOT, who serves as the Chief Executive Officer of the company, sold 50,459 shares for $133.79 each. As a result, the insider received 6,750,910 and left with 7,229 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AXSM now has a Market Capitalization of 6926696448 and an Enterprise Value of 6820020736. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.34 while its Price-to-Book (P/B) ratio in mrq is 93.76. Its current Enterprise Value per Revenue stands at 12.151 whereas that against EBITDA is -36.287.
Stock Price History:
The Beta on a monthly basis for AXSM is 0.48, which has changed by 0.51186 over the last 52 weeks, in comparison to a change of 0.1476624 over the same period for the S&P500. Over the past 52 weeks, AXSM has reached a high of $144.15, while it has fallen to a 52-week low of $75.56. The 50-Day Moving Average of the stock is 9.05%, while the 200-Day Moving Average is calculated to be 19.06%.
Shares Statistics:
It appears that AXSM traded 533.64K shares on average per day over the past three months and 624680 shares per day over the past ten days. A total of 50.31M shares are outstanding, with a floating share count of 41.79M. Insiders hold about 17.50% of the company’s shares, while institutions hold 75.75% stake in the company. Shares short for AXSM as of 1761868800 were 3604602 with a Short Ratio of 6.75, compared to 1759190400 on 3380948. Therefore, it implies a Short% of Shares Outstanding of 3604602 and a Short% of Float of 8.51.
Earnings Estimates
. The current rating of Axsome Therapeutics Inc (AXSM) is the result of assessments by 10.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.58, with high estimates of -$0.22 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$3.52 and -$4.28 for the fiscal current year, implying an average EPS of -$3.84. EPS for the following year is $0.58, with 13.0 analysts recommending between $3.14 and -$3.61.
Revenue Estimates
In. The current quarter, 17 analysts expect revenue to total $186.5M. It ranges from a high estimate of $194.07M to a low estimate of $180.94M. As of. The current estimate, Axsome Therapeutics Inc’s year-ago sales were $118.77MFor the next quarter, 17 analysts are estimating revenue of $190.1M. There is a high estimate of $203.7M for the next quarter, whereas the lowest estimate is $177.94M.
A total of 19 analysts have provided revenue estimates for AXSM’s current fiscal year. The highest revenue estimate was $636.57M, while the lowest revenue estimate was $505M, resulting in an average revenue estimate of $621.38M. In the same quarter a year ago, actual revenue was $385.69MBased on 18 analysts’ estimates, the company’s revenue will be $977.46M in the next fiscal year. The high estimate is $1.1B and the low estimate is $819M.
